These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 18986025

  • 1. [Pharmacoeconomic efficiency of sparfloxacin use in empiric therapy of community-acquired pneumonia].
    Lazareva NB.
    Antibiot Khimioter; 2007; 52(7-8):53-7. PubMed ID: 18986025
    [No Abstract] [Full Text] [Related]

  • 2. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS.
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [Abstract] [Full Text] [Related]

  • 3. [The clinical and pharmacoeconomic aspects of gemifloxacin(corrected) use in the patients with extra-hospital pneumonia in stationary conditions].
    Zaĭtsev AA, Sinopal'nikova AI.
    Voen Med Zh; 2007 Jan; 328(1):44-51. PubMed ID: 17436714
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
    Frei CR, Labreche MJ, Attridge RT.
    Drugs; 2011 Apr 16; 71(6):757-70. PubMed ID: 21504252
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S, Yanagihara K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Senjyu H, Saito A, Kohno S.
    J Infect; 2009 Sep 16; 59(3):222-4. PubMed ID: 19592113
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM, Restrepo MI, Anzueto A, Pugh J.
    Crit Care; 2005 Dec 06; 10(1):R8. PubMed ID: 16420641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.